CD8A and neoplasm: Anti‐hTAPBPL mAb treatment resulted in increased percentages of tumor‐infiltrating CD4+ and CD8+ T cells (Fig 7E–H and Fig EV5D), but decreased percentage of CD4+CD25+FoxP3+ Tregs (Fig 7I and J), as determined by flow cytometry.